SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

This is very interesting . leak from blinded

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Oren1976 Member Profile
 
Followed By 0
Posts 284
Boards Moderated 0
Alias Born 12/04/16
160x600 placeholder
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/21/2017 4:07:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 11/20/2017 5:18:37 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/20/2017 5:14:41 PM
VBL Therapeutics Prices  2.5 Million Ordinary Share Offering "GlobeNewswire Inc." - 11/17/2017 9:00:00 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) "Edgar (US Regulatory)" - 11/16/2017 5:15:46 PM
VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares "GlobeNewswire Inc." - 11/16/2017 4:01:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/14/2017 7:01:16 AM
VBL Therapeutics Announces Third Quarter 2017 Financial Results "GlobeNewswire Inc." - 11/14/2017 7:00:00 AM
VBL Therapeutics to Report Third Quarter 2017 Results on November 14 "GlobeNewswire Inc." - 11/7/2017 10:29:26 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/6/2017 6:35:59 AM
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters "GlobeNewswire Inc." - 10/23/2017 8:05:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/23/2017 8:01:41 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/20/2017 9:01:57 AM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) "Edgar (US Regulatory)" - 10/11/2017 4:32:10 PM
VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in... "GlobeNewswire Inc." - 10/2/2017 7:00:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 9/18/2017 5:15:09 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/13/2017 4:32:33 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 8/14/2017 5:38:30 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/14/2017 7:02:00 AM
VBL Therapeutics Announces Second Quarter 2017 Financial Results "GlobeNewswire Inc." - 8/14/2017 7:00:00 AM
VBL Therapeutics to Report Second Quarter 2017 Results on August 14 "GlobeNewswire Inc." - 8/2/2017 8:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 6/22/2017 4:35:22 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 6/19/2017 4:34:03 PM
VBL Therapeutics Provides Update on Long-Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types "GlobeNewswire Inc." - 6/19/2017 8:00:00 AM
VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer "GlobeNewswire Inc." - 6/15/2017 7:00:00 AM
Oren1976   Saturday, 05/20/17 12:27:33 AM
Re: davidal66 post# 953
Post # of 1657 
This is very interesting . leak from blinded data caused the selloff in march. We know the safety committee that see blinded data gathered in march. So now we have many signs of failure. I m also invested in tenx and there was similar selloff due to probably leak before they announced the failed phase 3 leaving me with huge loss. I still believe by the way tenx drug will be approved by fda although trial partially failed. Back to vblt ...so we have all the reason to run away but I stay why ? I know that at some point unfortunately people in the avastin arm will die one after another because avastin provoke the cancer to such an extent that when it overcome avastin it kills the patient fast

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist